A Randomized, Double Blind, Placebo Controlled, Single Oral Dose Study to Demonstrate the Safety, Tolerability, and Pharmacokinetics of ACP-104 (N-Desmethylclozapine) [norclozapine] in Schizophrenia, or Other Psychotic Disorders.
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2011
At a glance
- Drugs Norclozapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 14 Aug 2006 Status change
- 05 May 2006 New trial record.